Search

Issue
Title
Authors
Vol 11, No 4 (2015)
Prognostic factors of the therapeutic efficacy of mTOR and VEGFR inhibitors in patients with metastatic renal cell carcinoma
Voroshilova Е.А., Apanovich N.V., Nosov D.A., Karpukhin А.V., Sokolova I.N., Fedyanin M.Y.
PDF
(Rus)
Vol 12, No 1 (2016)
Use of sunitinib in patients with metastatic kidney cancer in real clinical practice
Alekseev B.Y., Nyushko K.M., Kalpinsky A.S.
PDF
(Rus) PDF
(Eng)
Vol 20, No 1 (2024)
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Grünwald V., Powles T., Eto M., Kopyltsov E., Rha S.Y., Porta C., Motzer R., Hutson T.E., Méndez-Vidal M.J., Hong S.H., Winquist E., Goh J.C., Maroto P., Buchler T., Takagi T., Burgents J.E., Perini R., He C., Okpara C.E., McKenzie J., Choueiri T.K.
PDF
(Rus)
Vol 11, No 2 (2015)
Neoadjuvant targeted therapy in patients with renal cell carcinoma
Alekseev B.Y., Nyushko K.M., Kalpinsky A.S.
PDF
(Rus)
Vol 19, No 4 (2023)
Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
Grünwald V., Powles T., Kopyltsov E., Kozlov V., Alonso-Gordoa T., Eto M., Hutson T., Motzer R., Winquist E., Maroto P., Keam B., Procopio G., Wong S., Melichar B., Rolland F., Oya M., Rodriguez-Lopez K., Saito K., McKenzie J., Porta C.
PDF
(Rus)
Vol 11, No 1 (2015)
Sorafenib is the first targeted agent to treat metastatic kidney cancer
Matveev V.B., Chernyaev V.A.
PDF
(Rus)
Vol 14, No 2 (2018)
Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma
Alekseev B.Y., Shevchuk I.M., Kaprin A.D.
PDF
(Rus)
Vol 5, No 4 (2009)
THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
Bhojani N., Jeldres C., Patard J., Perrotte P., Suardi N., Hutterer G., Patenaude F., Oudard S., Karakiewicz P.I.
PDF
(Rus)
Vol 12, No 4 (2016)
Clinical and economic analysis of the 1st and 2nd target lines
D’yakov I.N., Zyryanov S.K.
PDF
(Rus)
Vol 9, No 2 (2013)
PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY
Kharkevich G.Y., Demidov L.V.
PDF
(Rus)
Vol 12, No 3 (2016)
Optimization of sequential targeted therapy
Alekseev B.Y., Kalpinskiy A.S., Nyushko K.M., Taraki I.A., Kaprin A.D.
PDF
(Rus) PDF
(Eng)
Vol 6, No 2 (2010)
Practical recommendations for the prevention and correction of adverse reactions of sunitinib
Gutorov S.L., Borisova E.I.
PDF
(Rus)
Vol 12, No 1 (2016)
Clinical economic assessment of the use of pazopanib in the therapy of disseminated kidney cancer
Zyryanov S.K., Frolov M.Y., Dyakov I.N.
PDF
(Rus) PDF
(Eng)
1 - 13 of 13 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"